Bioaraba Health Research Institute Report issue

Academic/Hospital Phase 3 Phase 4

Organization Overview

First Clinical Trial
2020
NCT04621058
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Bioaraba | Bioaraba Health Research Institute | BIOARABA HRI

Active Ingredients

Drugs in Phase 4 Trials (1)

rituximab (rituxan) (1 trial)

Drugs in Phase 3 Trials (1)

vitamin d3 (1 trial)

Drugs in Other Trials (2)

acetylcysteine (mucomyst) (1 trial)

sucrose (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Pneumonia (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 4
  • # of Trial APIs: 4